Inhibitor Report for: Fragment-077

ESTHER: Willis_2022_J.Med.Chem__
PubMedSearch: Willis 2022 J.Med.Chem
PubMedID: 35536179
Gene_locus related to this paper: human-NOTUM
Inhibitor(s) related to this paper: ARUK3001043, Fragment-077, ARUK3001185

Abstract

Notum is a carboxylesterase that suppresses Wnt signaling through deacylation of an essential palmitoleate group on Wnt proteins. There is a growing understanding of the role Notum plays in human disease such as colorectal cancer and Alzheimer'ss disease supporting the need to discover improved inhibitors, especially for use in models of neurodegeneration. Here, we describe the discovery and profile of 8l (ARUK3001185) as a potent, selective and brain pentrant inhibitor of Notum activity suitable for oral dosing in rodent models of disease. Crystallographic fragment screening of the Diamond-SGC Poised Library for binding to Notum, supported by a biochemical enzyme assay to rank inhibition activity, identifed 6a and 6b as a pair of outstanding hits. Fragment development of 6 delivered 8l that restored Wnt signaling in the presence of Notum in a cell-based reporter assay. Assessment in pharmacology screens showed 8l to be selective against serine hydrolases, kinases and drug targets.

ESTHER: Zhao_2022_ACS.Chem.Neurosci_13_2060
PubMedSearch: Zhao 2022 ACS.Chem.Neurosci 13 2060
PubMedID: 35731924
Gene_locus related to this paper: human-NOTUM
Inhibitor(s) related to this paper: CHEMBL57478, ARUK3001043, Fragment-823, Fragment-828, Fragment-810, Fragment-872, Fragment-863, Fragment-791, Fragment-772, Fragment-784, Fragment-792, Fragment-705, Fragment-722, Fragment-714, Fragment-658, Fragment-690, Fragment-923, Fragment-924, Fragment-900, Fragment-916, Fragment-934, Fragment-955, Fragment-927, ARUK3000223, Fragment-886, Fragment-067, Fragment-074, Fragment-077, Fragment-065, Fragment-154, Fragment-159, Felbinac, Fragment-174, Fragment-173, Fragment-110, Sulfapyridine, Fragment-147, Fragment-297, Fragment-290, Fragment-201, Fragment-210, Fragment-283, Fragment-282, Fragment-277, Fragment-276, Fragment-197, Fragment-193, Fragment-199, Fragment-588, Fragment-609, Fragment-634, Fragment-646, Fragment-830, 2-N-pyridin-2-ylbenzene-1,2-diamine, (4-fluoroanilino)thiourea, Fragment-063-notum-screen, Fragment-064-notum-screen, Fragment-049-notum-screen, SCHEMBL21776992, 4F-329S, N-[2-(5-fluoro-1H-indol-3-yl)ethyl]acetamide, JVB, CHEMBL4539054, ARUK3001185

Abstract

The Wnt signaling suppressor Notum is a promising target for osteoporosis, Alzheimer's disease, and colorectal cancers. To develop novel Notum inhibitors, we used an X-ray crystallographic fragment screen with the Diamond-SGC Poised Library (DSPL) and identified 59 fragment hits from the analysis of 768 data sets. Fifty-eight of the hits were found bound at the enzyme catalytic pocket with potencies ranging from 0.5 to >1000 microM. Analysis of the fragments' diverse binding modes, enzymatic inhibitory activities, and chemical properties led to the selection of six hits for optimization, and five of these resulted in improved Notum inhibitory potencies. One hit, 1-phenyl-1,2,3-triazole 7, and its related cluster members, have shown promising lead-like properties. These became the focus of our fragment development activities, resulting in compound 7d with IC(50) 0.0067 microM. The large number of Notum fragment structures and their initial optimization provided an important basis for further Notum inhibitor development.